Lilly shot eloralintide shows 20% weight loss
Eli Lilly’s once‑weekly amylin receptor agonist eloralintide yielded 9.5%–20.1% average weight loss over 48 weeks in a 263‑person Phase 2 trial of adults with overweight or obesity without diabetes, according to results published in The Lancet and presented at ObesityWeek 2025 in Atlanta. The drug improved waist circumference, blood pressure, lipids, glycemic markers, and inflammation, was generally well tolerated with mainly GI side effects and fatigue, and Lilly plans Phase 3 studies by year‑end; it is not yet FDA‑approved.
Obesity and Weight-Loss Drugs
Pharmaceuticals and Clinical Trials
📌 Key Facts
- Phase 2, 263 adults, 48 weeks: 9.5%–20.1% weight loss vs 0.4% on placebo
- Published in The Lancet; presented at ObesityWeek 2025 (Atlanta)
- Mechanism: selective amylin receptor agonist; weekly injectable
- Reported improvements in BP, lipids, glycemic markers, inflammation
- Side effects: mostly mild/moderate GI symptoms and fatigue; higher at larger doses
- Lilly plans Phase 3 obesity studies by end of year; not FDA‑approved